38 results on '"Kahraman, Seda"'
Search Results
2. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases
- Author
-
Kahraman, Seda, Karakaya, Serdar, Kaplan, Muhammed Ali, Goksu, Sema Sezgin, Ozturk, Akin, Isleyen, Zehra Sucuoglu, Hamdard, Jamshid, Yildirim, Sedat, Dogan, Tolga, Isik, Selver, Celebi, Abdussamet, Gulbagci, Burcu Belen, Paksoy, Nail, Dogan, Mutlu, Turk, Haci Mehmet, Bilici, Ahmet, Tatli, Ali Murat, Akbas, Sinem, Turan, Nedim, Hacibekiroglu, Ilhan, Dogu, Gamze Gokoz, Aydiner, Adnan, Sumbul, Ahmet Taner, Akyurek, Serap, Yalciner, Merih, Demirkazik, Ahmet, Gursoy, Pinar, Aykan, Musa Baris, Sahin, Elif, Karadag, İbrahim, Kostek, Osman, Er, Muhammed Muhiddin, Artaç, Mehmet, Duzkopru, Yakup, Aydin, Dincer, Isik, Deniz, Karakas, Yusuf, Kilickap, Saadettin, Erol, Cihan, Demir, Bilgin, Civelek, Burak, Ergun, Yakup, Akinci, Muhammed Bulent, Dogan, Izzet, Karadurmus, Nuri, Yumuk, Perran Fulden, and Sendur, Mehmet Ali Nahit
- Published
- 2024
- Full Text
- View/download PDF
3. RETRACTED ARTICLE: Tarsoconjunctival Granulation Tissue Formation Associated with EGFR Inhibitors
- Author
-
Guler, Ferhan, Yuksel, Nilay, Kahraman, Seda, and Sendur, Mehmet Ali Nahit
- Published
- 2023
- Full Text
- View/download PDF
4. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)
- Author
-
Hizal, Mutlu, Bilgin, Burak, Paksoy, Nail, Atcı, Muhammed Mustafa, Kahraman, Seda, Kılıçkap, Saadettin, Güven, Deniz Can, Keskinkılıç, Merve, Ayhan, Murat, Eren, Önder, Mustafayev, Fatma Nihan Akkoç, Yaman, Şebnem, Bayram, Ertuğrul, Ertürk, İsmail, Özcan, Erkan, Korkmaz, Mustafa, Akagündüz, Baran, Erdem, Dilek, Telli, Tuğba Akın, Aksoy, Asude, Üskent, Necdet, Baytemür, Naziyet Köse, Gülmez, Ahmet, Aydın, Dinçer, Şakalar, Teoman, Arak, Hacı, Tatlı, Ali Murat, Ergün, Yakup, Ak, Naziye, Ünal, Çağlar, Özgün, Mehmet Alpaslan, Yalçın, Bülent, Öztop, İlhan, Algın, Efnan, Sakin, Abdullah, Aydıner, Adnan, Yumuk, Perran Fulden, and Şendur, Mehmet Ali Nahit
- Published
- 2023
- Full Text
- View/download PDF
5. Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
- Author
-
Karacin, Cengiz, Oksuzoglu, Berna, Demirci, Ayşe, Keskinkılıç, Merve, Baytemür, Naziyet Köse, Yılmaz, Funda, Selvi, Oğuzhan, Erdem, Dilek, Avşar, Esin, Paksoy, Nail, Demir, Necla, Göksu, Sema Sezgin, Türker, Sema, Bayram, Ertuğrul, Çelebi, Abdüssamet, Yılmaz, Hatice, Kuzu, Ömer Faruk, Kahraman, Seda, Gökmen, İvo, Sakin, Abdullah, Alkan, Ali, Nayır, Erdinç, Uğraklı, Muzafer, Acar, Ömer, Ertürk, İsmail, Demir, Hacer, Aslan, Ferit, Sönmez, Özlem, Korkmaz, Taner, Celayir, Özde Melisa, Karadağ, İbrahim, Kayıkçıoğlu, Erkan, Şakalar, Teoman, Öktem, İlker Nihat, Eren, Tülay, Erul, Enes, Mocan, Eda Eylemer, Kalkan, Ziya, Yıldırım, Nilgün, Ergün, Yakup, Akagündüz, Baran, Karakaya, Serdar, Kut, Engin, Teker, Fatih, Demirel, Burçin Çakan, Karaboyun, Kubilay, Almuradova, Elvina, Ünal, Olçun Ümit, Oyman, Abdilkerim, Işık, Deniz, Okutur, Kerem, Öztosun, Buğra, Gülbağcı, Burcu Belen, Kalender, Mehmet Emin, Şahin, Elif, Seyyar, Mustafa, Özdemir, Özlem, Selçukbiricik, Fatih, Kanıtez, Metin, Dede, İsa, Gümüş, Mahmut, Gökmen, Erhan, Yaren, Arzu, Menekşe, Serkan, Ebinç, Senar, Aksoy, Sercan, İmamoğlu, Gökşen İnanç, Altınbaş, Mustafa, Çetin, Bülent, Uluç, Başak Oyan, Er, Özlem, Karadurmuş, Nuri, Erdoğan, Atike Pınar, Artaç, Mehmet, Tanrıverdi, Özgür, Çiçin, İrfan, Şendur, Mehmet Ali Nahit, Oktay, Esin, Bayoğlu, İbrahim Vedat, Paydaş, Semra, Aydıner, Adnan, Salim, Derya Kıvrak, Geredeli, Çağlayan, Yavuzşen, Tuğba, Doğan, Mutlu, and Hacıbekiroğlu, İlhan
- Published
- 2023
- Full Text
- View/download PDF
6. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
- Author
-
Karacin, Cengiz, Oksuzoglu, Berna, Demirci, Ayşe, Keskinkılıç, Merve, Baytemür, Naziyet Köse, Yılmaz, Funda, Selvi, Oğuzhan, Erdem, Dilek, Avşar, Esin, Paksoy, Nail, Demir, Necla, Göksu, Sema Sezgin, Türker, Sema, Bayram, Ertuğrul, Çelebi, Abdüssamet, Yılmaz, Hatice, Kuzu, Ömer Faruk, Kahraman, Seda, Gökmen, İvo, Sakin, Abdullah, Alkan, Ali, Nayır, Erdinç, Uğraklı, Muzaffer, Acar, Ömer, Ertürk, İsmail, Demir, Hacer, Aslan, Ferit, Sönmez, Özlem, Korkmaz, Taner, Celayir, Özde Melisa, Karadağ, İbrahim, Kayıkçıoğlu, Erkan, Şakalar, Teoman, Öktem, İlker Nihat, Eren, Tülay, Urul, Enes, Mocan, Eda Eylemer, Kalkan, Ziya, Yıldırım, Nilgün, Ergün, Yakup, Akagündüz, Baran, Karakaya, Serdar, Kut, Engin, Teker, Fatih, Demirel, Burçin Çakan, Karaboyun, Kubilay, Almuradova, Elvina, Ünal, Olçun Ümit, Oyman, Abdilkerim, Işık, Deniz, Okutur, Kerem, Öztosun, Buğra, Gülbağcı, Burcu Belen, Kalender, Mehmet Emin, Şahin, Elif, Seyyar, Mustafa, Özdemir, Özlem, Selçukbiricik, Fatih, Kanıtez, Metin, Dede, İsa, Gümüş, Mahmut, Gökmen, Erhan, Yaren, Arzu, Menekşe, Serkan, Ebinç, Senar, Aksoy, Sercan, İmamoğlu, Gökşen İnanç, Altınbaş, Mustafa, Çetin, Bülent, Uluç, Başak Oyan, Er, Özlem, Karadurmuş, Nuri, Erdoğan, Atike Pınar, Artaç, Mehmet, Tanrıverdi, Özgür, Çiçin, İrfan, Şendur, Mehmet Ali Nahit, Oktay, Esin, Bayoğlu, İbrahim Vedat, Paydaş, Semra, Aydıner, Adnan, Salim, Derya Kıvrak, Geredeli, Çağlayan, Yavuzşen, Tuğba, Doğan, Mutlu, and Hacıbekiroğlu, İlhan
- Published
- 2023
- Full Text
- View/download PDF
7. Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study
- Author
-
Yıldırım, Hasan Çağrı, Mutlu, Emel, Chalabiyev, Elvin, Özen, Miraç, Keskinkılıç, Merve, Ön, Sercan, Çelebi, Abdussamet, Dursun, Bengü, Acar, Ömer, Kahraman, Seda, Aykan, Musa Barış, Kaman, Ömür, Doğan, Akif, Erdoğan, Atike Pınar, Melisa Celayir, Özde, Günenç, Damla, Güven, Deniz Can, Vedat Bayoğlu, İbrahim, Yavuzşen, Tuğba, Hacıbekiroğlu, İlhan, İnanç, Mevlüde, Kılıçkap, Saadettin, Yalçın, Şuayib, and Aksoy, Sercan
- Published
- 2022
- Full Text
- View/download PDF
8. Effectiveness of simplified predictive intubation difficulty score and thyromental height in head and neck surgeries: an observational study
- Author
-
Selvi, Onur, Kahraman, Seda Tugce, Tulgar, Serkan, Senturk, Ozgur, Serifsoy, Talat Ercan, Thomas, David, Cinar, Ayse Surhan, and Ozer, Zeliha
- Published
- 2020
- Full Text
- View/download PDF
9. Eficácia do escore simplificado preditivo de dificuldade de intubação e da altura tiromentoniana em cirurgias de cabeça e pescoço: estudo observacional
- Author
-
Selvi, Onur, Kahraman, Seda Tugce, Tulgar, Serkan, Senturk, Ozgur, Serifsoy, Talat Ercan, Thomas, David, Cinar, Ayse Surhan, and Ozer, Zeliha
- Published
- 2020
- Full Text
- View/download PDF
10. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey
- Author
-
Akyildiz, Arif, primary, Guven, Deniz Can, additional, Ozluk, Ahmet Anil, additional, Ismayilov, Rashad, additional, Mutlu, Emel, additional, Unal, Olcun Umit, additional, Yildiz, Ibrahim, additional, Iriagac, Yakup, additional, Turhal, Serdar, additional, Akbas, Sinem, additional, Bayram, Ertugrul, additional, Telli, Tugba Akin, additional, Turkoz, Fatma Paksoy, additional, Ozcelik, Melike, additional, Erciyestepe, Mert, additional, Selvi, Oguzhan, additional, Gulbagci, Burcu, additional, Erturk, Ismail, additional, Isleyen, Zehra Sucuoglu, additional, Kahraman, Seda, additional, Akdag, Mutianur Ozkorkmaz, additional, Hamitoglu, Buket, additional, Unek, Ilkay Tugba, additional, Unal, Caglar, additional, Hacibekiroglu, İlhan, additional, Arslan, Cagatay, additional, Azizy, Abdulmunir, additional, Helvaci, Kaan, additional, Demirci, Umut, additional, Dizdar, Omer, additional, Basaran, Mert, additional, Goker, Erdem, additional, Sendur, Mehmet Ali, additional, and Yalcin, Suayib, additional
- Published
- 2023
- Full Text
- View/download PDF
11. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group
- Author
-
Erol, Cihan, Sendur, Mehmet Nahit, Bilgetekin, Irem, Garbioglu, Duygu, Hamdard, Jamshid, Akbas, Sinem, Hizal, Mutlu, Arslan, Cagatay, Sevinc, Alper, Kucukarda, Ahmet, Erdem, Dilek, Kahraman, Seda, Cakir, Emre, Demirkiran, Aykut, On, Sercan, Dogan, Izzet, Erdogan, Atike, Koca, Sinan, Kubilay, Pinar, Eren, Orhan, Cilbir, Ebru, Celik, Emir, Araz, Murat, Ozyukseler, Deniz, Yildirim, Mahmut, Bahceci, Aykut, Taskaynatan, Halil, Oyman, Abdilkerim, Deniz, Gulhan, Menekse, Serkan, Kut, Engin, Gulmez, Ahmet, Sakin, Abdullah, Nayir, Erdinc, Acar, Ramazan, Sen, Erdem, Inal, Ali, Turhal, Serdar, Kaya, Ali, Paydas, Semra, Tastekin, Didem, Hacibekiroglu, Ilhan, Cincin, Irfan, Bilici, Ahmet, Mandel, Nil, Dede, Didem, Akinci, Muhammed, Oksuzoglu, Berna, Uncu, Dogan, Yalcin, Bulent, and Artac, Mehmet
- Subjects
Metastasis -- Drug therapy -- Patient outcomes ,Fluorouracil -- Dosage and administration -- Patient outcomes ,Colorectal cancer -- Drug therapy -- Patient outcomes ,Drug therapy, Combination -- Patient outcomes ,Health - Abstract
Byline: Cihan. Erol, Mehmet. Nahit Sendur, Irem. Bilgetekin, Duygu. Garbioglu, Jamshid. Hamdard, Sinem. Akbas, Mutlu. Hizal, Cagatay. Arslan, Alper. Sevinc, Ahmet. Kucukarda, Dilek. Erdem, Seda. Kahraman, Emre. Cakir, Aykut. Demirkiran, [...]
- Published
- 2022
12. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study
- Author
-
Goktas Aydin, Sabin, primary, Kavak, Engin Eren, additional, Topcu, Atakan, additional, Bayramgil, Ayberk, additional, Akgul, Fahri, additional, Kahraman, Seda, additional, Aykan, Musa Baris, additional, Altıntas, Yunus Emre, additional, Helvaci, Kaan, additional, Urun, Yuksel, additional, Bilici, Ahmet, additional, Seker, Mesut, additional, Sendur, Mehmet Ali Nahit, additional, Olmez, Omer Fatih, additional, Acikgoz, Ozgur, additional, and Cicin, Irfan, additional
- Published
- 2023
- Full Text
- View/download PDF
13. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
- Author
-
Kahraman, Seda, primary, Erul, Enes, additional, Seyyar, Mustafa, additional, Gumusay, Ozge, additional, Bayram, Ertugrul, additional, Demirel, Burcin Cakan, additional, Acar, Omer, additional, Aksoy, Sercan, additional, Baytemur, Naziyet Kose, additional, Sahin, Elif, additional, Cabuk, Devrim, additional, Basaran, Gul, additional, Paydas, Semra, additional, Yaren, Arzu, additional, Guven, Deniz Can, additional, Erdogan, Atike Pinar, additional, Demirci, Umut, additional, Yasar, Alper, additional, Bayoglu, İbrahim Vedat, additional, Hizal, Mutlu, additional, Gulbagci, Burcu, additional, Paksoy, Nail, additional, Davarci, Sena Ece, additional, Yilmaz, Funda, additional, Dogan, Ozlem, additional, Orhan, Sibel Oyucu, additional, Kayikcioglu, Erkan, additional, Aytac, Ali, additional, Keskinkilic, Merve, additional, Mocan, Eda Eylemer, additional, Unal, Olcun Umit, additional, Aydin, Esra, additional, Yucel, Hakan, additional, Isik, Deniz, additional, Eren, Onder, additional, Uluc, Basak Oyan, additional, Ozcelik, Melike, additional, Hacibekiroglu, Ilhan, additional, Aydiner, Adnan, additional, Demir, Hacer, additional, Oksuzoglu, Berna, additional, Cilbir, Ebru, additional, Cubukcu, Erdem, additional, Cetin, Bulent, additional, Oktay, Esin, additional, Erol, Cihan, additional, Okutur, Sadi Kerem, additional, Yildirim, Nilgun, additional, Alkan, Ali, additional, Selcukbiricik, Fatih, additional, Aksoy, Asude, additional, Karakas, Yusuf, additional, Ozkanli, Gulhan, additional, Duman, Berna Bozkurt, additional, Aydin, Dincer, additional, Dulgar, Ozgecan, additional, Er, Muhammed Muhiddin, additional, Teker, Fatih, additional, Yavuzsen, Tugba, additional, Aykan, Musa Baris, additional, Inal, Ali, additional, Iriagac, Yakup, additional, Kalkan, Nurhan Onal, additional, Keser, Murat, additional, Sakalar, Teoman, additional, Menekse, Serkan, additional, Kut, Engin, additional, Bilgin, Burak, additional, Karaoglanoglu, Muge, additional, Sunar, Veli, additional, Ozdemir, Ozlem, additional, Turhal, Nazim Serdar, additional, Karadurmus, Nuri, additional, Yalcin, Bulent, additional, and Nahit Sendur, Mehmet Ali, additional
- Published
- 2023
- Full Text
- View/download PDF
14. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
- Author
-
Selçukbiricik, Fatih (ORCID 0000-0002-1273-1674 & YÖK ID 202015), Karacin, Cengiz; Oksuzoglu, Berna; Demirci, Ayşe; Keskinkılıç, Merve; Baytemür, Naziyet Köse; Yılmaz, Funda; Selvi, Oğuzhan; Erdem, Dilek; Avşar, Esin; Paksoy, Nail; Demir, Necla; Göksu, Sema Sezgin; Türker, Sema; Bayram, Ertuğrul; Çelebi, Abdüssamet; Yılmaz, Hatice; Kuzu, Ömer Faruk; Kahraman, Seda; Gökmen, İvo; Sakin, Abdullah; Alkan, Ali; Nayır, Erdinç; Uğraklı, Muzaffer; Acar, Ömer; Ertürk, İsmail; Demir, Hacer; Aslan, Ferit; Sönmez, Özlem; Korkmaz, Taner; Celayir, Özde Melisa; Karadağ, İbrahim; Kayıkçıoğlu, Erkan; Şakalar, Teoman; Öktem, İlker Nihat; Eren, Tülay; Urul, Enes; Mocan, Eda Eylemer; Kalkan, Ziya; Yıldırım, Nilgün; Ergün, Yakup; Akagündüz, Baran; Karakaya, Serdar; Kut, Engin; Teker, Fatih; Demirel, Burçin Çakan; Karaboyun, Kubilay; Almuradova, Elvina; Ünal, Olçun Ümit; Oyman, Abdilkerim; Işık, Deniz; Okutur, Kerem; Öztosun, Buğra; Gülbağcı, Burcu Belen; Kalender, Mehmet Emin; Şahin, Elif; Seyyar, Mustafa; Özdemir, Özlem; Kanıtez, Metin; Dede, İsa; Gümüş, Mahmut; Gökmen, Erhan; Yaren, Arzu; Menekşe, Serkan; Ebinç, Senar; Aksoy, Sercan; İmamoğlu, Gökşen İnanç; Altınbaş, Mustafa; Çetin, Bülent; Uluç, Başak Oyan; Er, Özlem; Karadurmuş, Nuri; Erdoğan, Atike Pınar; Artaç, Mehmet; Tanrıverdi, Özgür; Çiçin, İrfan; Şendur, Mehmet Ali Nahit; Oktay, Esin; Bayoğlu, İbrahim Vedat; Paydaş, Semra; Aydıner, Adnan; Salim, Derya Kıvrak; Geredeli, Çağlayan; Yavuzşen, Tuğba; Doğan, Mutlu; Hacıbekiroğlu, İlhan, School of Medicine, Selçukbiricik, Fatih (ORCID 0000-0002-1273-1674 & YÖK ID 202015), Karacin, Cengiz; Oksuzoglu, Berna; Demirci, Ayşe; Keskinkılıç, Merve; Baytemür, Naziyet Köse; Yılmaz, Funda; Selvi, Oğuzhan; Erdem, Dilek; Avşar, Esin; Paksoy, Nail; Demir, Necla; Göksu, Sema Sezgin; Türker, Sema; Bayram, Ertuğrul; Çelebi, Abdüssamet; Yılmaz, Hatice; Kuzu, Ömer Faruk; Kahraman, Seda; Gökmen, İvo; Sakin, Abdullah; Alkan, Ali; Nayır, Erdinç; Uğraklı, Muzaffer; Acar, Ömer; Ertürk, İsmail; Demir, Hacer; Aslan, Ferit; Sönmez, Özlem; Korkmaz, Taner; Celayir, Özde Melisa; Karadağ, İbrahim; Kayıkçıoğlu, Erkan; Şakalar, Teoman; Öktem, İlker Nihat; Eren, Tülay; Urul, Enes; Mocan, Eda Eylemer; Kalkan, Ziya; Yıldırım, Nilgün; Ergün, Yakup; Akagündüz, Baran; Karakaya, Serdar; Kut, Engin; Teker, Fatih; Demirel, Burçin Çakan; Karaboyun, Kubilay; Almuradova, Elvina; Ünal, Olçun Ümit; Oyman, Abdilkerim; Işık, Deniz; Okutur, Kerem; Öztosun, Buğra; Gülbağcı, Burcu Belen; Kalender, Mehmet Emin; Şahin, Elif; Seyyar, Mustafa; Özdemir, Özlem; Kanıtez, Metin; Dede, İsa; Gümüş, Mahmut; Gökmen, Erhan; Yaren, Arzu; Menekşe, Serkan; Ebinç, Senar; Aksoy, Sercan; İmamoğlu, Gökşen İnanç; Altınbaş, Mustafa; Çetin, Bülent; Uluç, Başak Oyan; Er, Özlem; Karadurmuş, Nuri; Erdoğan, Atike Pınar; Artaç, Mehmet; Tanrıverdi, Özgür; Çiçin, İrfan; Şendur, Mehmet Ali Nahit; Oktay, Esin; Bayoğlu, İbrahim Vedat; Paydaş, Semra; Aydıner, Adnan; Salim, Derya Kıvrak; Geredeli, Çağlayan; Yavuzşen, Tuğba; Doğan, Mutlu; Hacıbekiroğlu, İlhan, and School of Medicine
- Abstract
Background: there is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). Methods: a total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ? 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. Results: the median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0–14.0) months in the ET arm of group A, and 5.3 (3.9–6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8–7.7) months in the ET arm of group B, and 5.7 (4.6–6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5–8.0) months in the ET arm of group C and 4.0 (3.5–4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. Conclusion: physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that be, NA
- Published
- 2023
15. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study.
- Author
-
Aydin, Sabin Goktas, Kavak, Engin Eren, Topcu, Atakan, Bayramgil, Ayberk, Akgul, Fahri, Kahraman, Seda, Aykan, Musa Baris, Altintas, Yunus Emre, Helvaci, Kaan, Urun, Yuksel, Bilici, Ahmet, Seker, Mesut, Nahit Sendur, Mehmet Ali, Olmez, Omer Fatih, Acikgoz, Ozgur, and Cicin, Irfan
- Published
- 2023
- Full Text
- View/download PDF
16. Geriatrik hastada dental uygulama esnasında implant anahtarının aspirasyonu: vaka raporu
- Author
-
Günbay, Tayfun, Kenç, Selin, Işık, Gözde, Kahraman, Seda, and Çelik, Ferit
- Subjects
Health Care Sciences and Services ,Geriatric dentistry,implant screwdriver,aspiration,fluoroscopy ,bronchoscopy ,Geriatrik diş hekimliği ,implant anahtarı ,aspirasyon ,floroskopi ,bronkoskopi ,Sağlık Bilimleri ve Hizmetleri - Abstract
The aim of this case report is to present a geriatric patient who had aspirated an implant screwdriver. An 82-year-old male patient involuntarily closed his mouth during the healing cap placement phase of implant treatment, and the implant screwdriver disappeared through the pharynx. As the patient exhibited no signs of airway obstruction, it was considered that the implant screwdriver might have passed into the gastrointestinal tract. However, no foreign object was detected in the esophageal mucosa. Therefore, the procedure was repeated using C arm fluoroscopy for guidance. The examination revealed the presence of the implant screwdriver in the bifurcation of the left lower lobe bronchus, which was confirmed by posterior-anterior chest radiography. The following day, the patient underwent a flexible bronchoscopy, however the screwdriver could not be retrieved during the procedure. Further treatment was refused by the patient. After one month, the implant screwdriver was expelled through the gastrointestinal tract. At the three-year follow-up, there was no evidence of a late complication. Aspiration of screwdrivers and treatment failures of these complications are reported a small number of cases in the geriatric patients. Therefore, documentation of the rare cases is necessary to provide valuable information., Bu vaka raporunun amacı, implant anahtarını aspire etmiş geriatrik bir hastayı sunmaktır. Seksen iki yaşında erkek hasta, implant tedavisinin bir aşaması olan iyileşme başlığının takılması esnasında istemsizce ağzını kapatmış ve implant anahtarı farinkse doğru yer değiştirmiştir. Hastada hava yolu tıkanıklığı bulguları olmadığı için, implant anahtarının gastrointestinal yolağa doğru hareket ettiği düşünülmüştür; ancak özefageal mukozada yabancı cisim saptanmamıştır. Bu nedenle, uygulama C arm floroskopi rehberliğinde tekrarlanmıştır. Değerlendirmede implant anahtarının sol alt lob bronş girişinde olduğu düşünülmüştür ve bu bulgu, posteroanteriyor göğüs radyografisi ile doğrulanmıştır. Takip eden günde, hasta fiberoptik fleksibl bronkoskopiye alınmıştır; ancak implant anahtarı çıkartılamamıştır. İmplant anahtarının çıkarılmasında yaşanılan başarısızlıktan dolayı, hasta tarafından ileri tedaviler reddedilmiştir. Bir ay sonra, implant anahtarı gastrointestinal yolaktan atılmıştır. Üç yıllık takipte, geç dönem komplikasyon ile karşılaşılmamıştır. Geriatrik hastalarda, implant anahtarının yutulması ve bu komplikasyonun tedavisindeki başarısızlıklar az sayıda vaka raporunda bildirilmiştir. Bu nedenle, bu nadir vakaların belgelenmesi, faydalı bilgilerin sağlanması açısından gereklidir.
- Published
- 2022
- Full Text
- View/download PDF
17. Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience
- Author
-
EROL, Cihan, primary, BARDAKÇI, Murat, additional, HIZAL, Mutlu, additional, KAHRAMAN, Seda, additional, YEKEDÜZ, Emre, additional, GÜVEN, Deniz Can, additional, AYKAN, Musa Barış, additional, AK, Recep, additional, ATEŞ, Öztürk, additional, ŞENER DEDE, Didem, additional, AKINCI, Muhammed Bülent, additional, KARADURMUŞ, Nuri, additional, BAL, Öznur, additional, ÜRÜN, Yüksel, additional, YALÇIN, Şuayib, additional, YALÇIN, Bülent, additional, and ŞENDUR, Mehmet Ali Nahit, additional
- Published
- 2023
- Full Text
- View/download PDF
18. Tarsoconjunctival Granulation Tissue Formation Associated with EGFR Inhibitors
- Author
-
Guler, Ferhan, primary, Yuksel, Nilay, additional, Kahraman, Seda, additional, and Sendur, Mehmet Ali Nahit, additional
- Published
- 2022
- Full Text
- View/download PDF
19. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)
- Author
-
Hizal, Mutlu, primary, Bilgin, Burak, additional, Paksoy, Nail, additional, Atcı, Muhammed Mustafa, additional, Kahraman, Seda, additional, Kılıçkap, Saadettin, additional, Güven, Deniz Can, additional, Keskinkılıç, Merve, additional, Ayhan, Murat, additional, Eren, Önder, additional, Mustafayev, Fatma Nihan Akkoç, additional, Yaman, Şebnem, additional, Bayram, Ertuğrul, additional, Ertürk, İsmail, additional, Özcan, Erkan, additional, Korkmaz, Mustafa, additional, Akagündüz, Baran, additional, Erdem, Dilek, additional, Telli, Tuğba Akın, additional, Aksoy, Asude, additional, Üskent, Necdet, additional, Baytemür, Naziyet Köse, additional, Gülmez, Ahmet, additional, Aydın, Dinçer, additional, Şakalar, Teoman, additional, Arak, Hacı, additional, Tatlı, Ali Murat, additional, Ergün, Yakup, additional, Ak, Naziye, additional, Ünal, Çağlar, additional, Özgün, Mehmet Alpaslan, additional, Yalçın, Bülent, additional, Öztop, İlhan, additional, Algın, Efnan, additional, Sakin, Abdullah, additional, Aydıner, Adnan, additional, Yumuk, Perran Fulden, additional, and Şendur, Mehmet Ali Nahit, additional
- Published
- 2022
- Full Text
- View/download PDF
20. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study
- Author
-
Hizal, Mutlu, primary, Bilgin, Burak, additional, Paksoy, Nail, additional, Kılıçkap, Saadettin, additional, Atcı, Muhammed Mustafa, additional, Kahraman, Seda, additional, Keskinkılıç, Merve, additional, Bilgetekin, İrem, additional, Ayhan, Murat, additional, Tural, Deniz, additional, Eren, Önder, additional, Akkoç Mustafayev, Fatma Nihan, additional, Yaman, Şebnem, additional, Tatlı, Ali Murat, additional, Bayram, Ertuğrul, additional, Kutlu, Yasin, additional, Ertürk, İsmail, additional, Özcan, Erkan, additional, Gülmez, Ahmet, additional, Korkmaz, Mustafa, additional, Akagündüz, Baran, additional, Erdem, Dilek, additional, Telli, Tuğba Akın, additional, Aksoy, Asude, additional, Üskent, Necdet, additional, İriağaç, Yakup, additional, Baytemür, Naziyet Köse, additional, Aydın, Dinçer, additional, Şakalar, Teoman, additional, Arak, Hacı, additional, Selçukbiricik, Fatih, additional, Ergün, Yakup, additional, Korkmaz, Taner, additional, Ak, Naziye, additional, Ünal, Çağlar, additional, Akdeniz, Nadiye, additional, Özgün, Mehmet Alpaslan, additional, Öksüzoğlu, Berna, additional, Yalçın, Bülent, additional, Öztop, İlhan, additional, Algın, Efnan, additional, Sakin, Abdullah, additional, Aydıner, Adnan, additional, Yumuk, Perran Fulden, additional, and Nahit Şendur, Mehmet Ali, additional
- Published
- 2022
- Full Text
- View/download PDF
21. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)
- Author
-
Yumuk, Perran Fulden, Hızal, Mutlu; Bilgin, Burak; Paksoy, Nail; Atçı, Muhammed Mustafa; Kahraman, Seda; Kılıçkap, Saadettin; Güven, Deniz Can; Keskinkılıç, Merve; Ayhan, Murat; Eren, Önder; Mustafayev, Fatma Nihan Akkoç; Yaman, Şebnem; Bayram, Ertuğrul; Ertürk, İsmail; Özcan, Erkan; Korkmaz, Mustafa; Akagündüz, Baran; Erdem, Dilek; Telli, Tugba Akin; Aksoy, Asude; Uskent, Necdet; Baytemur, Naziyet Köse; Gülmez, Ahmet; Aydın, Dinçer; Sakalar, Teoman; Arak, Hacı; Tatlı, Ali Murat; Ergün, Yakup; Ak, Naziye; Ünal, Çağlar; Özgün, Mehmet Alpaslan; Yalçın, Bülent; Öztop, İlhan; Algın, Efnan; Sakin, Abdullah; Aydıner, Adnan; Sendur, Mehmet Ali Nahit, School of Medicine, Yumuk, Perran Fulden, Hızal, Mutlu; Bilgin, Burak; Paksoy, Nail; Atçı, Muhammed Mustafa; Kahraman, Seda; Kılıçkap, Saadettin; Güven, Deniz Can; Keskinkılıç, Merve; Ayhan, Murat; Eren, Önder; Mustafayev, Fatma Nihan Akkoç; Yaman, Şebnem; Bayram, Ertuğrul; Ertürk, İsmail; Özcan, Erkan; Korkmaz, Mustafa; Akagündüz, Baran; Erdem, Dilek; Telli, Tugba Akin; Aksoy, Asude; Uskent, Necdet; Baytemur, Naziyet Köse; Gülmez, Ahmet; Aydın, Dinçer; Sakalar, Teoman; Arak, Hacı; Tatlı, Ali Murat; Ergün, Yakup; Ak, Naziye; Ünal, Çağlar; Özgün, Mehmet Alpaslan; Yalçın, Bülent; Öztop, İlhan; Algın, Efnan; Sakin, Abdullah; Aydıner, Adnan; Sendur, Mehmet Ali Nahit, and School of Medicine
- Abstract
Introduction Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced ALK-positive NSCLC. Recent studies demonstrated that the percentage of ALK-positive tumor cells in patient groups receiving crizotinib might affect outcomes. This study aimed to investigate whether the percentage of ALK-positive cells had a predictive effect in patients with advanced NSCLC who received first-line Alectinib as ALK-TKI. Materials and methods This retrospective study included patients with advanced-stage NSCLC who received alectinib as a first-line ALK-TKI and whose percentage of ALK-positive cells was determined by FISH at 27 different centers. Patients who received any ALK-TKI before alectinib were not included in the study. Patients were separated into two groups according to the median (40%) value of the percentage of ALK-positive cells (high-positive group >= 40% and low-positive group < 40%). The primary endpoint was PFS, and the secondary endpoints were OS, ORR, and PFS of the subgroups based on different threshold values for the percentage of ALK-positive cells. Results 211 patients were enrolled (48.3% female, 51.7% male) to study. 37% (n = 78) of the patients had received chemotherapy previously. After a median of 19.4 months of follow-up, the median PFS was not reached in the high-positive group (n = 113), but it was 10.8 months in the low-positive group (n = 98) (HR 0.39; 95% CI 0.25-0.60, p < 0.001). The median OS in the high-positive group was not reached, whereas it was 22.8 months in the low-positive group (HR 0.37; 95% CI 0.22-0.63, p < 0.001). ORR was significantly higher in the high-positive group (87.2 vs. 68.5%; p = 0.002). According to the cut-off values of < 20%, 20-39%, 40-59%, and >= 60%, the median PFS was 4.5, 17.1, and 26 months, respectively, and could not be reached in the >= 60% group. Conclusion Our study demonstrated that the efficacy of alectinib varies significantly ac, NA
- Published
- 2022
22. Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations.
- Author
-
Kahraman, Seda, Bardakci, Murat, Aykan, Musa B., Yasar, Serkan, Erol, Cihan, Hizal, Mutlu, Bulent Akinci, M., Kos, Fahriye Tugba, Dede, Didem S., Karadurmus, Nuri, Yalcin, Suayib, Sendur, Mehmet Ali N., and Yalcin, Bulent
- Subjects
- *
NEUROENDOCRINE tumors , *LOG-rank test , *PANCREATIC tumors , *NEUROENDOCRINE system , *CLINICAL pathology , *RETROSPECTIVE studies - Abstract
Objective: Neuroendocrine neoplasms(NENs) originate from the diffuse neuroendocrine cell system and constitute a heterogeneous group of tumors exhibiting diverse clinical and biological characteristics. NENs include well‑differentiated neuroendocrine tumors(NETs) and poorly differentiated neuroendocrine carcinomas (NECs). In the present study, we performed a retrospective analysis of patients diagnosed with NET to evaluate clinicopathological characteristics, treatment and outcomes. Material and Methods: Data from 153 patients diagnosed with NET who were treated and followed up at three tertiary care centers from November 2002 to June 2021 were retrospectively evaluated. Clinicopathological and prognostic factors, treatment modalities and survival data were analyzed. Kaplan–Meier analysis was used to assess survival data and comparisons were performed using the logrank test. Results: Median age (IQR) was 53 (18–80) years. 85.6% of the patients had gastro‑entero‑pancreatic (GEP)‑NET. The primary tumor was resected in 95 patients (62.1%) and metastasectomy were performed in 22 patients (14.4%). Seventy‑eight patients received systemic therapy for metastatic disease. Patients were followed up for a median of 22 (IQR = 33.8) months. The estimated one‑year and three‑year survival rate was 89.8% and 74.4%, respectively. Median progression‑free survival (PFS) were 10.1, 8.5, and 4.2 months after first‑, second‑ and third‑line therapy, respectively. Conclusion: The number of systemic treatment options and diagnostic tools for NETs has significantly improved in the last few years. NET classification, which treatment will be more appropriate for which group of patients, the molecular basis of this disease and the development of treatment strategies are open‑ended questions that still need to be investigated. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Predictive and Prognostic Value of ABO Blood Group in Patients Using Immune Checkpoint Inhibitor for Advanced Renal Cell Carcinoma
- Author
-
ERGÜN, Yakup, primary, UÇAR, Gökhan, additional, AKTÜRK ESEN, Selin, additional, BARDAKÇI, Murat, additional, KALKAN, Ziya, additional, URAKÇI, Zuhat, additional, ŞEYRAN, Erdoğan, additional, DOĞAN, Mutlu, additional, İMAMOĞLU, Gökşen İnanç, additional, YAZICI, Ozan, additional, KAHRAMAN, Seda, additional, AÇIKGÖZ, Yusuf, additional, and UNCU, Doğan, additional
- Published
- 2022
- Full Text
- View/download PDF
24. We need a common definition and treatment algorithm for displaced rib fracture
- Author
-
Kavurmacı, Önder, primary, Aydın, Sercan, additional, Gülmez, Barış, additional, Kahraman, Seda, additional, Akçam, Tevfik İlker, additional, Özdil, Ali, additional, Ergönül, Ayşe Gül, additional, Akçay, Onur, additional, Yoldaş, Banu, additional, Türker, Asuman Akın, additional, Zorlu, Ekin, additional, and Karakılıç, Ali, additional
- Published
- 2022
- Full Text
- View/download PDF
25. Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer
- Author
-
Kahraman,Seda and Yalcin,Suayib
- Subjects
OncoTargets and Therapy - Abstract
Seda Kahraman,1 Suayib Yalcin2 1Yıldırım Beyazıt University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey; 2Hacettepe University Institute of Cancer, Department of Medical Oncology, Ankara, TurkeyCorrespondence: Suayib YalcinHacettepe University Institute of Cancer, Department of Medical Oncology, Sıhhiye, Ankara, TurkeyTel +90-5053780639Email syalcin@hacettepe.edu.trAbstract: Gastric cancer (GC) is the fifth most common cancer worldwide. Despite recent improvements in treatment quality and options, advanced gastric cancer remains one of the hardest to cure cancers, with a median overall survival (OS) of 10â 12 months and a 5-year OS of approximately 5â 20%. There is an unmet need for further efforts to palliate disease-related symptoms, improve quality of life, increase tumor response rate, and prolong progression free and overall survival while balancing the toxicities of therapy. The most common type of GC is adenocarcinoma, which demonstrates morphological, biological, and clinical heterogeneity. A plethora of genomic alterations and the activation of numerous molecular pathways including human epidermal growth receptor 2 (HER2), epidermal growth factor receptor (EGFR), fibroblast growth factor receptor-2 (FGFR2), mesenchymal epidermal transforming factor receptor (MET), and the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) are responsible for the complex heterogeneity of GC. Efforts to validate the therapeutic effects of inhibiting some of these aberrantly expressed pathways have failed to lead to a clinically meaningful outcome apart from the overexpression/amplification of the HER2 gene, inhibition of which has had a significant impact on clinical practice. The only available biomarkers to guide the effective treatment of patients with advanced GC are HER2 overexpression, MSI/PD-L1 status, and FGFR alterations. Various anti-HER2 agents have been evaluated after the success of the ToGA trial, but none led to a significant enough clinical improvement to be considered a viable alternative for HER2-targeted therapy in advanced GC until the global Keynote-811 trial, which added pembrolizumab to trastuzumab in combination with chemotherapy. This combination demonstrated a survival advantage for the first time in the 11 years since ToGA. Trastuzumab deruxtecan (T-DXd) was also found to be effective in patients who had already received > 2 previous lines of treatment. Despite these promising avenues, the optimal management of HER-2 positive GC still requires further development.Keywords: gastric cancer, HER-2, trastuzumab, targeted therapy
- Published
- 2021
26. Birinci basamak alektinib tedavisi alan ALK mutasyonu pozitif akciğer kanseri hastalarının klinik özelliklerinin değerlendirilmesi
- Author
-
Hızal, Mutlu, primary, Bilgin, Burak, additional, Şendur, Mehmet Ali, additional, Yücel, Şebnem, additional, Kahraman, Seda, additional, Erol, Cihan, additional, Akıncı, Bülent, additional, Şener Dede, Didem, additional, Algın, Efnan, additional, and Yalçın, Bülent, additional
- Published
- 2021
- Full Text
- View/download PDF
27. A Generalized Construction for Perfect Autocorrelation Sequences
- Author
-
Özbudak, Ferruh, Tekin, Eda, Kahraman, Seda, Bortaş,, Serdar, Özbudak, Ferruh, Tekin, Eda, Kahraman, Seda, and Bortaş,, Serdar
- Abstract
In this paper we generalize a previous construction in order to design perfect autocorrelation sequences over the so-called PSK+ constellation defined by Boztas, and Udaya [2]. We give a number theoretic criterion for the existence of the new sequences with perfect autocorrelation, and discuss some preliminary numerical results on their aperiodic correlations and merit factors., IEEE, IEEE Informat Theory Soc, HUAWEI, VTECH, Qualcomm, Google, Croucher Fdn, IBM, BROADCOM, Mediatek, iSN State Key Lab, INC, ITS, SENG, Hong Kong Polytechn Univ, K C Wong Educ Fdn, NSF, Hong Kong Univ Sci ; Technol, Sch Engn
- Published
- 2021
28. Birinci basamak alektinib tedavisi alan ALK mutasyonu pozitif akciğer kanseri hastalarının klinik özelliklerinin değerlendirilmesi.
- Author
-
HIZAL, Mutlu, BİLGİN, Burak, ŞENDUR, Mehmet Ali, YÜCEL, Şebnem, KAHRAMAN, Seda, EROL, Cihan, AKINCI, Bülent, ŞENER DEDE, Didem, ALGIN, Efnan, and YALÇIN, Bülent
- Published
- 2021
- Full Text
- View/download PDF
29. Polikistik over sendromu'nda serum dipeptidil peptidaz-4 (DPP-4), adenozin deaminaz (ADA) aktiviteleri ve oksidatif stres belirteçlerinin değerlendirilmesi
- Author
-
Kahraman, Seda, Eroğlu Altınova, Alev, and İç Hastalıkları Anabilim Dalı
- Subjects
Adenosine deaminase ,Oxidative stress ,Endocrinology and Metabolic Diseases ,Endokrinoloji ve Metabolizma Hastalıkları ,Dipeptidyl-peptidases and tripeptidyl-peptidases ,Polycystic ovary syndrome - Abstract
Polikistik over sendromu (PKOS), yalnızca reprodüktif bir hastalık olmayıp aynı zamanda uzun vadeli sağlık riskleri ile ilişkili görülen heterojen, metabolik bir hastalıktır. İnsülin direncinin ve metabolik bozuklukların yanı sıra, PKOS'lu kadınlarda, kronik düşük dereceli inflamasyon ve artmış oksidatif stres gösterilmiştir. DPP-4 enziminin metabolik ve inflamatuar hastalıkların patofizyolojisinde rol oynayabileceği düşünülmektedir. DPP-4 ayrıca ADA enzimiyle bağlanmaktadır. ADA ile DPP-4'ün etkileşimi, T hücre proliferasyonunda artış ve sitokin sentezi ile sonuçlanmaktadır. ADA aktivitesinin artması halinde, azalan adenozin düzeyleri ile birlikte insülin direnci, hücre proliferasyonu, inflamasyonun indükleneceği öne sürülmektedir. Bu çalışmada, PKOS'lu hastalarda insülin direnci ve inflamasyon ile ilişkili olan DPP-4 ve ADA aktivitelerini, oksidatif stres parametrelerinden serum NO düzeyi ve NOS aktivitesini kontrollerle karşılaştırmalı bir şekilde ölçmeyi, kendi aralarında ve metabolik parametrelerle olası ilişkilerini incelemeyi planladık. Ayrıca obez ve nonobez olarak 2 altgruba ayırdığımız hasta ve kontrol grubunu aynı parametreler açısından araştırdık. Çalışmaya PKOS'lu 52 kadın ve 41 sağlıklı kontrol alındı. PKOS'lu hasta ve kontrol grubunun DPP-4 aktivite düzeyleri benzer tespit edildi (19,54 ± 7,01 ve 18,24 ± 6,73 IU/l; p=0,369). Serum ADA aktivite düzeyleri PKOS grubunda kontrol grubuna göre istatiksel olarak anlamlı şekilde yüksek bulundu (0,33 (0,17-0,67) ve 0,26 (0,12-0,60) IU/l; p=0,006). Serum NO düzeyleri PKOS grubunda kontrol grubuna göre istatiksel olarak anlamlı şekilde yüksek bulundu (24,5 (13,25-58) ve 12,25 (6-24,50) µmol/l; p
- Published
- 2017
30. Association of Serum Betatrophin with Fibroblast Growth Factor-21 in Women with Polycystic Ovary Syndrome
- Author
-
KAHRAMAN, Seda, primary, EROĞLU ALTINOVA, Alev, additional, YALÇIN, Mehmet Muhittin, additional, GÜLBAHAR, Özlem, additional, ARSLAN, Burak, additional, AKTÜRK, Müjde, additional, ÇAKIR, Nuri, additional, and BALOŞ TÖRÜNER, Füsun, additional
- Published
- 2018
- Full Text
- View/download PDF
31. Siyanobakteriler ve toksinleri
- Author
-
Kahraman, Seda Dicle, Küplülü, Özlem, Meslek Yüksekokulları, Espiye Meslek Yüksekokulu, Gıda İşleme Bölümü, and Kahraman, Seda Dicle
- Subjects
Siyanotoksin ,Siyanobakter,siyanotoksin,su hijyeni ,Su Hijyeni ,Siyanobakter ,Cyanobacteria,cyanotoxin,water hygiene - Abstract
Tatlı su kaynakları açısından son derece zengin olan ülkemizde su kirliliğinin artışı siyanobakteriyel toksinlerin yaratacağı risklerin önemli bir işareti olmaktadır. Plansız yerleşim ve sanayi atıklarının hemen hemen hiç işlem görmeden iç sulara deşarj edilmesi bu durumun en önemli nedeni olup birçok göl, baraj gölü ve akarsuda su kalitesinin bozulmasına ve siyanobakteriyel kümelerin oluşumuna ortam hazırlamaktadır. Yüzey sularında ötrofi kasyonla birlikte aşırı alg artışı, suların kullanımını sınırlamakta, toksik türlerin bir araya gelmesiyle dünyadaki su kaynakları ve kıyı sularında insan sağlığı için büyük bir tehlike oluşmaktadır.İçerdikleri fotosentetik pigmentler nedeniyle mavi yeşil algler olarak adlandırılan siyanobakterilerin karasal ve kıyı sularında bulunan en az 46 türü omurgalılarda toksik etki oluşturmaktadır. Bu toksinler etkileri açısından; hepatotoksin, nörotoksin ve sitotoksinler olarak sınıfl andırılmakta olup, kimyasal olarak da siklik peptitler (hepatotoksik, mikrosistin ve nodularin), alkaloidler (nörotoksik, anatoksin ve saksitoksin) ve LPS (Lipopolisakarit) endotoksinler olarak üç ayrı grupta incelenmektedirler. Bu derlemede, siyanobakterilerin toksinleri ve yapıları, etki mekanizmaları, sağlık üzerine etkileri, siyanotoksin içeren suların arıtılması ve içme sularında buna ilişkin yapılan düzenlemeler konusunda derlenen bilgiler sunulacaktır, Even though we are rich in fresh water resources, the increase in water pollution is a sign of a signifi cant increase in the risks created by cyanobacterial toxins. Unplanned urban settlements and industrial waste discharge are the most important reasons for this situation and this also prepares the ground for the water quality degradation at many lakes, dam lakes and rivers and the formation of cyanonabacterial clusters. Eutrophication in surface waters with excessive algae growth, restricts the usage of water, and with the combination of toxic species in coastal waters human health is put in great danger.Because of the fact that blue-green algae cyanobactacretrias contain photosynthetic pigments, they have toxic effects on at least 46 types of vertebrates that live in interrestrialand coastal waters. Based on their effects, these toxins are classifi ed as hepatotoxin, neurotoxin and sitotoxins, and chemically they are analyzed in three separate groups: cyclic peptides (hepatotoxic, microcystins and nodular), alkaloids (neurotoxic, anatoxin and saksitoxin) and LPS. In this paper, cyanobacteria toxins and their structures, effect mechanisms, their effects on health, water treatment containing cyanotoxin and arrangements on drinking water will be discussed
- Published
- 2012
32. Optimal frekans atlamalı diziler
- Author
-
Saygı, Zülfikar, Kahraman, Seda, Saygı, Zülfikar, and Kahraman, Seda
- Abstract
Bu tezin amacı, Frekans Atlamalı Kod Bölü¸sümlü Çoklu Eri¸sim1 (FH-CDMA), Bluetoothve ultra geni¸s bant gibi popüler sistemlerde kullanılan Optimal Frekans Atlamalı Dizilerin(FHS lerin) olu¸sturulmasıdır. Literatürde optimalli?gi belirleyen sınırlar bulunmaktadır. Buradakioptimallik Lempel-Greenberger ve Peng-Fan anlamındadır. Bu tezde, 1974 den bugüneyayımlanmı¸s optimal FHS üretim metodları incelenmi¸s ve bir tabloda toplanmı¸stır. AyrıcaLempel-Greenberger Sınırı nın keskin bir sınır olup olmadı?gının incelenmesi için 1974 teyayımlamı¸s makalede bulunun optimallik sınırı ve ispatı verilmi¸stir. FHS lerin olu¸sturulmasındakullanılan cebirsel, kombinatorik vs. gibi bir çok metod vardır. Bunların içindencebirsel bir üretim metodu olan ?Iz Fonksiyonu ile üretim yapan 4 makale incelenmi¸s ve bunlarınMAGMA ile gerçekle¸stirimi yapılarak örnekleri incelenmi¸stir. Ayrıca girilen parametreleregöre FHS olu¸sturan yeni bir MAGMA kodu yazılmı¸stır ve yeni optimal dizilerin varlı?gıincelenmi¸stir. Sabit parametreler için optimal FHS ler bulunmu¸stur ancak bunlar henüz birkurala oturtulamamaktadır. Yeni optimal FHS üretim arayı¸sımız devam etmekte olup ilerleyençalı¸smalarımızda, ?Iz Fonksiyonunun yanı sıra di?ger üretim metodları için de benzer bir çalı¸smayürütülebilir.The purpose of this thesis is constructing Optimal Frequency Hopping Sequences (FHSs)which are used in popular systems such as Frequency Hopping-Code Division Multiple Access(FH-CDMA), Bluetooth and Ultra-Wide Band. There are bounds in literature determining optimality.The optimality here is by means of Lempel-Greenberger and Peng-Fan. In this thesis,construction methods of optimal FHSs published since 1974 are analysed and gathered in atable. In addition, so as to examine the sharpness of Lempel-Greenberger Bound, the optimalitybound and its proof given in the paper published in 1974 take place. There are severalmethods for constructing optimal FHSs like algebraic, combinatorial e.t.c.. Four papers givingalgeb
- Published
- 2016
33. Süzme ballarda muhafaza sıcaklığının HMF değeri ve diastaz aktivitesi üzerine etkisi
- Author
-
Kahraman, Seda Dicle, Küplülü, Özlem, and Besin Hijyeni ve Teknolojisi Anabilim Dalı
- Subjects
Food preservation ,Kardiyoloji ,Amylases ,Cardiology ,Hydroxymethylfurfural ,Chromatography-high pressure-liquid ,Honey - Abstract
Bu araştırmada Türkiye'de farklı firmalarca üretilen süzme çiçek ve salgı balı örneklerinin HMF miktarı ve diastaz aktivitesi üzerine farklı muhafaza sıcaklıklarının etkisinin ortaya konulması amaçlanmıştır. Ayrıca farklı satış noktalarından orijinal ambalajlarında alınan süzme ballar, HMF miktarı ve diastaz aktivitesi yönünden analiz edilerek Türk Gıda Kodeksi (T.G.K.) Bal Tebliği'ne göre uygunlukları değerlendirilmiştir.Çalışma kapsamında fabrikalardan dolum tarihlerinde alınan A, B, C, D, E markalarına ait süzme çiçek ve salgı balı örneklerinin kalite kriterleri (nem, şeker, pH, asitlik, elektriksel iletkenlik, kül) belirlenerek başlangıç (0. gün) HMF ve diastaz aktiviteleri saptanmıştır. Örnekler, belirli sıcaklıklarda (10±2 °C , 22±2 °C , 35±2 °C) muhafaza edilerek üç aylık periyotlar (3., 6., 9. ve 12. ay) sonunda HMF ve diastaz aktivitesi yönünden analize alınmıştır. Çalışmanın piyasa taraması bölümünde, farklı satış noktalarından alınan 25 çiçek ve 25 salgı olmak üzere toplam 50 süzme bal örneğinin HMF miktarı ve diastaz aktivitesi saptanarak fruktoz, glikoz ve sakkaroz içerikleri ile birlikte değerlendirilmiştir. Örneklerin HMF miktarları Yüksek Performans Sıvı Kromatografisi (HPLC), diastaz aktiviteleri UV Spektrofotometre ile belirlenmiştir.Elde edilen bulgulara göre, bir yıl boyunca 10±2 °C ve 22±2 °C'de muhafaza edilen çiçek ve salgı balı örneklerinin ortalama HMF değerleri T.G.K. Bal Tebliği'nde sınır HMF değeri olarak belirtilen 40 mg/kg`ı aşmazken, 35±2 °C'de muhafaza edilen örneklerde hızla artarak 6. aydan itibaren 40 mg/kg üzerinde saptanmıştır. Ayrıca örneklerin bir yıl boyunca 10±2 °C ve 22±2 °C'deki ortalama diastaz aktiviteleri T.G.K. Bal Tebliği'nce belirtilen sınır değer olan 8'in altına düşmezken 35±2 °C'de muhafaza edilen çiçek balları için bu değer 6. aydan itibaren 8'in altında saptanmıştır.Yine çalışma kapsamında, farklı satış noktalarından alınarak HMF değeri ve diastaz aktivitesi belirlenen bal örneklerinin analiz sonuçlarına göre; 25 çiçek balı örneğinden 2'si HMF değeri, 1'i diastaz aktivitesi, 7'si ise HMF değeri ve diastaz aktivitesi yönünden, 25 salgı balı örneğinden 4'ü HMF değeri, 1'i ise HMF değeri ve diastaz aktivitesi yönünden T.G.K Bal Tebliği'nde sınır HMF değeri olarak belirtilen 40 mg/kg ile en az 8 olması gereken diastaz aktivite değerine uygun olmadığı saptanmıştır.Sonuç olarak tüketime sunulan süzme ballarda, gerek üretim sırasında uygulanan ısı işlemi, gerekse muhafaza sıcaklığına bağlı olarak artan HMF değeri ile azalan diastaz aktivitesi firmalarca belirlenen raf ömrünü kısaltmaktadır. Balda oluşan HMF'nin gıda güvenliği ve halk sağlığı yönünden potansiyel risk olduğu bilinmektedir. Bala ait uygun üretim ve muhafaza koşulları sağlanarak, başta HMF ve diastaz olmak üzere tüm kalite kriterlerinin Türk Gıda Kodeksi Bal Tebliği'ne uygunluğu raf ömrünün sonuna kadar sağlanmalıdır.Anahtar Sözcükler : Bal, Diastaz aktivitesi, HMF, HPLC, Muhafaza Sıcaklığı This research aims to document the effect of the storage conditions on the HMF value and distase activity of flower and honeydrew honey samples collected from several producers. Besides, jar-packed strained honey samples collected at several markets were also analyzed for HMF value and diastase activity so as to evaluate their suitability to Turkish Food Codex.Strain flower and honeydrew honey samples, which collected from five companies (A, B, C, D, E) after filling proccess, were considered for different quality criteria (pH, acidity, electrical conductivity,mousture, ash, sugar) and their initial HMF values and diastase activities were determined. Honey samples were stored under different temperatures (10, 22, 35 °C) and analyzed per three monthly period in a year (3rd, 6th., 9th and 12th) for HMF value and diastase activity. In order to analyzed the honey samples in market level, 25 flower and 25 honeydrew honey samples were collected various stores and their HMF values and diastase activities were analyzed, considered together with the fructose, glucose, saccarose contents. HMF values and diastase activities of samples were determined by HPLC (High Performance Liquid Chromotography) and U.V. spectrophotometer, respectively.According to the findings, while the average HMF values of strain flower and honeydrew honey samples which were stored at 10±2 °C and 22±2 °C for a year did not exceed the limit value ( 40 mg/kg) recommended in the Turkish Food Codex, the ones stored at 35±2 °C showed a rapid increase in HMF values after six month storage. Furthermore, diastase activities of the above mentioned samples stored at 10±2 °C ve 22±2 °C did not drop below the Turkish Food Contex criteria (8
- Published
- 2012
34. Trans fatty acids
- Author
-
KAHRAMAN, Seda Dicle and KÜPLÜLÜ, Özlem
- Subjects
Food safety,hydrogenation,public health,trans fatty acid ,Trans yağ asidi,hidrojenasyon,gıda güvenliği,halk sağlığı - Abstract
Doymamış yağ asitlerinin karbonları arasındaki çift bağlara hidrojen ilavesi olarak tanımlanan hidrojenasyon, yağlarda oksidasyona duyarlılığı azaltarak tat stabilitesini artırmak ve fiziksel özellikleri değiştirerek, ürünün kullanım alanlarını artırmak amacıyla gıda endüstrisinde uygulanmaktadır. Ancak işlem sırasında cis formlara göre acil zinciri daha doğrusal, erime noktası ve termodinamik stabilitesi yüksek trans yağ asitleri (TYA) oluşmaktadır. Diyetteki trans yağ asitlerinin %82-90’ı endüstriyel kaynaklı kısmi hidrojenasyon işlemleri sonucu oluşurken, %2-8’i hayvansal ürünlerden kaynaklanmaktadır. Dünyanın pek çok yerinde gıda endüstrisinin vazgeçilmezi olan hidrojene yağlar, margarin ve şortening formülasyonlarında yer alarak TYA alım kaynağı olmaktadır. TYA, metabolizmada doymuş yağ gibi etki göstererek LDL kolesterol miktarını artırırken HDL kolesterol miktarını düşürmektedir.Yapılan epidemiyolojik çalışmalarla, TYA tüketimi ile kardiyovasküler hastalıkların oluşum riski arasında pozitif bir korelasyon olduğu ortaya konulmuştur. Ayrıca enzim sisteminde, prostaglandin sentezini baskılayarak sağlık açısından önem taşıyan metabolitlerin sentezini engellemektedir. Bu derlemede TYA, oluşum mekanizmaları, gıdalardaki varlığı ve ülkelerdeki tüketim durumu, insan sağlığı üzerine etkileri ile yasal düzenlemeler konusunda özetlenen bilgiler sunulmuştur, Hydrogenation is described as the addition of hydrogen to the dual bonds between the unsaturated fatty acids carbons. It is applied in the food industry so as to increase the stability of the taste by minimizing the sensitivity of the fats to oxidation and to increase the asge of the product by altering the features. Hydrogenation, by changing the chemical, physical properties of the fat, makes the fat appropriate to be uset in the production of several foods. Yet, during this process trans fatty acids (TFA), which are of higher thermodynamical stability and melting point, are formed. Also, the chains of “acil” TFA are more linear in comparison to the one of the cis forms. While 82-90 % of TFA in diet result from industrial hydrogenation, 2-8% is sourced from animal products. Hydrogenated fats are the sources of TFA in the food industry by taking part in margarine and shortening formulations. TFA, increase the LDL cholesterol level by acting as saturated fats in the metabolism, on the other hand do decrease the HDL level. The epidemiogical studies indicate o positive correlation between TFA consumption and risk of cardio vascular diseases. Furthermore, TFA prevent th synthesis of the crucial metabolites by suppressing the synthesis of prostaglandin. This compliation presents on the formation mechanism, presence in food, the consumption levels, on the health effects and labeling legislation of TFA.
- Published
- 2011
35. Optimal frekans atlamalı diziler
- Author
-
Kahraman, Seda, Saygı, Zülfikar, Saygı, Zülfükar, and Matematik Ana Bilim Dalı
- Subjects
Matematik ,MATHEMATICS [Research Subject Categories] ,%22">Frekans atlamalı dizi üretim yöntemleri =Construction methods of optimal frequency hopping sequences,Optimal frekans atlamalı dizi çiftleri = Optimal frequency hopping sequence pairs,Optimal frekans atlamalı dizi ailesi =Optimal frequency hopping sequence families, Lempel- Greenberger sınırı =Lempel - Greenberger bound,Frekans atlamalı diziler =Frequency hopping sequences,Optimal frekans atlamalı diziler =Optimal frequency hopping sequences. ,Mathematics - Abstract
Bu tezin amacı, Frekans Atlamalı Kod Bölü¸sümlü Çoklu Eri¸sim1 (FH-CDMA), Bluetoothve ultra geni¸s bant gibi popüler sistemlerde kullanılan Optimal Frekans Atlamalı Dizilerin(FHS lerin) olu¸sturulmasıdır. Literatürde optimalli?gi belirleyen sınırlar bulunmaktadır. Buradakioptimallik Lempel-Greenberger ve Peng-Fan anlamındadır. Bu tezde, 1974 den bugüneyayımlanmı¸s optimal FHS üretim metodları incelenmi¸s ve bir tabloda toplanmı¸stır. AyrıcaLempel-Greenberger Sınırı nın keskin bir sınır olup olmadı?gının incelenmesi için 1974 teyayımlamı¸s makalede bulunun optimallik sınırı ve ispatı verilmi¸stir. FHS lerin olu¸sturulmasındakullanılan cebirsel, kombinatorik vs. gibi bir çok metod vardır. Bunların içindencebirsel bir üretim metodu olan ?Iz Fonksiyonu ile üretim yapan 4 makale incelenmi¸s ve bunlarınMAGMA ile gerçekle¸stirimi yapılarak örnekleri incelenmi¸stir. Ayrıca girilen parametreleregöre FHS olu¸sturan yeni bir MAGMA kodu yazılmı¸stır ve yeni optimal dizilerin varlı?gıincelenmi¸stir. Sabit parametreler için optimal FHS ler bulunmu¸stur ancak bunlar henüz birkurala oturtulamamaktadır. Yeni optimal FHS üretim arayı¸sımız devam etmekte olup ilerleyençalı¸smalarımızda, ?Iz Fonksiyonunun yanı sıra di?ger üretim metodları için de benzer bir çalı¸smayürütülebilir. The purpose of this thesis is constructing Optimal Frequency Hopping Sequences (FHSs)which are used in popular systems such as Frequency Hopping-Code Division Multiple Access(FH-CDMA), Bluetooth and Ultra-Wide Band. There are bounds in literature determining optimality.The optimality here is by means of Lempel-Greenberger and Peng-Fan. In this thesis,construction methods of optimal FHSs published since 1974 are analysed and gathered in atable. In addition, so as to examine the sharpness of Lempel-Greenberger Bound, the optimalitybound and its proof given in the paper published in 1974 take place. There are severalmethods for constructing optimal FHSs like algebraic, combinatorial e.t.c.. Four papers givingalgebraic construction via trace function are analysed and their examples are builded by implementingconstruction methods in MAGMA. Additionally, a MAGMA code is implemented inorder to construct FHSs for entered parameters and new existing optimal FHSs are searched.There are optimal FHSs for some fixed parameters, but there is not captured any pattern yet.Our search for optimal FHS construction is not finished. In our future study, we are planningto do the same study that we have done for Trace function for other techniques. 91
- Published
- 2011
36. A Rare Case of Metachronous Tumor: Recurrent Primary Lung Cancer.
- Author
-
Bakali HE, Kahraman S, Ergonul AG, and Ozyigit Buyuktalanci D
- Abstract
Multiple primary lung cancers (MPLC) are defined as lung cancers that develop at the time of primary lung cancer detection (synchronous) or during the follow-up period (metachronous). The incidence of MPLC is increasing due to the early detection of lesions by widespread screening methods, improved surgical, medical, and radiation treatment options, and increased survival. We present a case of a patient who was operated on in our clinic and diagnosed with primary lung cancer for the third time with different histopathology. Although rare, we wanted to emphasize that the follow-up and treatment planning for MPLCs, whose incidence is increasing, should be a multidisciplinary approach., Competing Interests: Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Bakali et al.)
- Published
- 2024
- Full Text
- View/download PDF
37. Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group).
- Author
-
Erol C, Sakin A, Başoğlu T, Özden E, Çabuk D, Doğan M, Öksüzoğlu B, Yıldırım HÇ, Öner İ, Eryılmaz MK, Dülgar Ö, Aydın D, Doğan N, Özen M, Hacıbekiroğlu İ, Özdemir N, Gürler F, Paksoy N, Karabulut S, Aksoy A, Hızal M, Kahraman S, Şen E, Paydaş S, Çılbır E, Fırat F, Akdeniz N, Özçelik M, Oyman A, Baytemür NK, Acar R, Almuradova E, Karabulut B, Şakalar T, Arak H, Değerli E, Türker S, Alan Ö, Er Ö, Taşçı EŞ, Demir N, Çavdar E, Turhal S, Dede DŞ, Akıncı MB, Yalçın B, Yumuk F, Yalçın Ş, and Şendur MAN
- Subjects
- Humans, Middle Aged, Prognosis, Retrospective Studies, Turkey epidemiology, Antineoplastic Combined Chemotherapy Protocols, Esophagogastric Junction pathology, Stomach Neoplasms drug therapy, Stomach Neoplasms surgery, Stomach Neoplasms pathology
- Abstract
Background: Perioperative FLOT regimen is a standard of care in locally advanced operable gastric and GEJ adenocarcinoma. We aimed to determine the efficacy, prognostic factors of perioperative FLOT chemotherapy in real-life gastric and GEJ tumors., Methods: The data of patients who were treated with perioperative FLOT chemotherapy were retrospectively analyzed from 34 different oncology centers in Turkey. Baseline clinical and demographic characteristics, pretreatment laboratory values, histological and molecular characteristics were recorded., Results: A total of 441 patients were included in the study. The median of age our study population was 60 years. The majority of patients with radiological staging were cT3-4N(+) (89.9%, n = 338). After median 13.5 months (IQR: 8.5-20.5) follow-up, the median overall survival was NR (95% CI, NR to NR), and median disease free survival was 22.9 (95% CI, 18.6 to 27.3) months. The estimated overall survival at 24 months was 62%. Complete pathological response (pCR) and near pCR was achieved in 23.8% of all patients. Patients with lower NLR or PLR have significantly longer median OS (p = 0.007 and p = 0.033, respectively), and patients with lower NLR have significantly longer median DFS (p = 0.039), but PLR level did not affect DFS (p = 0.062). The OS and DFS of patients with better ECOG performance scores and those who could receive FLOT as adjuvant chemotherapy instead of other regimens were found to be better. NLR was found to be independent prognostic factor for OS in the multivariant analysis. At least one adverse event reported in 57.6% of the patients and grade 3-4 toxicity was seen in 23.6% patients., Discussion: Real-life perioperative FLOT regimen in operable gastric and GEJ tumors showed similar oncologic outcomes compared to clinical trials. Better performance status, receiving adjuvant chemotherapy as same regimen, low grade and low NLR and PLR improved outcomes in real-life. However, in multivariate analysis, only NLR affected OS.
- Published
- 2022
- Full Text
- View/download PDF
38. [Clinical features of the ALK-mutant non-small cell lung cancer patients who received first-line alectinib treatment].
- Author
-
Hızal M, Bilgin B, Şendur MA, Yücel Ş, Kahraman S, Erol C, Akıncı B, Şener Dede D, Algın E, and Yalçın B
- Subjects
- Anaplastic Lymphoma Kinase genetics, Carbazoles, Crizotinib, Female, Humans, Male, Middle Aged, Piperidines, Protein Kinase Inhibitors therapeutic use, Retrospective Studies, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms drug therapy, Lung Neoplasms genetics
- Abstract
Introduction: Lung cancer is the most common cancer type and the leading cause of cancer-related mortality worldwide. The positivity rate of the anaplastic lymphoma kinase (ALK) mutation in non-small cell lung cancer (NSCLC) patients has been reported as 3-7%. This study aimed to investigate the pathological, clinical and demographic characteristics of ALK-mutant NSCLC patients who received first-line alectinib as a tyrosine kinase inhibitor in two different centers., Materials and Methods: The study was performed at the Medical Oncology Departments of Ankara City Hospital and Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital. Patients diagnosed with ALK-mutant NSCLC and received alectinib treatment as a first-line tyrosine kinase inhibitor were enrolled to study and retrospectively analyzed., Result: A total of 38 patients (15 males, 23 females) were included in the study. Median age was 56.5. 55.3% of the patients were non-smokers. All of the patients had adenocarcinoma histology. Thirty-four patients (89.5%) were metastatic. Brain metastasis was detected in 44.7% of the patients. Thirty-three patients (86.8%) were using alectinib in first-line treatment. The remaining five patients were seen to have received at least one course of chemotherapy before. The objective response rate was 78.9% with alectinib treatment. The percentage of the patients who experienced at least one side effect was 34.2% and serious side effects were 7.9%. After median 9.5 months follow-up, median progression-free survival (PFS) was not achieved. 24-month PFS was 67% and 24-month overall survival was 84%., Conclusions: Our results were compatible with previous studies in terms of the clinical, pathological and demographic features of the patients with ALK mutation. We observed that the majority of patients were non-smokers, relatively young, and female patients. The objective response rate and survival results were similar with phase 3 studies.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.